NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.

Strategic Overview
for the Year ended March 31, 2018

The output from each of the analysis is converted to a risk weight equivalent. Each of the four components of the risk analysis are assigned a specific
weight which differ based on type of investment. The risk weight is then converted into capital requirement. The required capital and the return is
combined to create a metric which is used for deal assessment.

Based on the above assessment the risk team categorises the deals in to the below Risk Grades

– Good Deals with very high risk adjusted returns

Management Discussion & Analysis

– Investment Grade Deals with high risk adjusted returns
– Management Review Grade Deals with risk adjusted returns required as per lending policy
– Not Advisable Grade Deals with lower than required risk adjusted returns

Further, a periodic review of the performance of the portfolio is also carried out by the Risk Group. The Risk Group adjusts the stress case considered
during the initial approval based on actual performance of the deal, developments in the sector, regulatory changes etc. The deal level output is
combined to form a portfolio snapshot. The trends from portfolio are used to provide strategic inputs to the management.

The credit risk on liquid funds and other financial instruments is limited because the counterparties are banks with high credit-ratings assigned by
credit-rating agencies or mutual funds.

Provision for Expected Credit Loss

Board & Management Profiles

The Group considers the probability of default upon initial recognition of asset and whether there has been a significant increase in credit risk on
an ongoing basis throughout each reporting period. To assess whether there is a significant increase in credit risk the Group compares the risk of a
default occurring on the asset as at the reporting date with the risk of default as at the date of initial recognition. It considers available reasonable
and supportive forward-looking parameters, which are both qualitative and quantitative. These parameters have been detailed in Note no.vii of
Significant Accounting Policies. Based on the result yielded by the above assessment the Financial assets are classified into (1) Standard (Performing)
Asset, (2) Significant Credit Deteriorated (Under-Performing) Asset (3) Default (Non-Performing) Asset (Credit Impaired).

Macroeconomic information (such as regulatory changes, market interest rate or growth rates) is incorporated as part of the internal rating model.

In general, it is presumed that credit risk has significantly increased since initial recognition if the payments are more than 30 days past due.
For the purpose of expected credit loss analysis the Group defines default as any asset with more than 90 days overdues. This is also as per the

Statutory Reports
rebuttable presumption provided by the standard.

The Group provides for expected credit loss based on the following:
Category – Description Basis for Recognition of Expected Credit Loss
Stage 1 – Standard (Performing) Assets 12 month ECL
Stage 2 – Significant Credit Deteriorated Assets Life time ECL
Stage 3 – Default (Non-Performing) Assets (Credit Impaired) Life time ECL

The Company has developed a PD Matrix consisting of various parameters suitably tailored for various facilities like grade of the borrower, past
overdue history, status from monthly asset monitoring report, deal IRR, deal tenure remaining etc.

Based on these parameters the Company has computed the PD. The Company has also built in model scorecard to determine the internal LGD.
Financial Statements

However, since there has been no default history to substantiate the internal LGD, the Company has made use of a combination of both internal as
well as external LGD.

Annual Report 2017-18 | 379

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

Expected Credit Loss as at the end of the reporting period:

(` in Crores)
As at March 31, 2018

Particulars Carrying Amount

Gross Carrying
Asset Group Expected Credit Loss net of impairment
Amount (Exposure)
provision
Very High quality liquid assets Other Financial Assets and Loans to 1,104.11 - 1,104.11
related parties and others
Assets for which credit risk has not significantly increased Investments at amortised cost 18,673.04 284.41 18,388.63
from initial recognition
Loans at amortised cost 21,838.95 353.24 21,485.71
Assets for which credit risk has increased significantly but Investments at amortised cost 268.09 10.07 258.02
are not credit impaired
Loans at amortised cost 59.26 1.58 57.68
Assets for which credit risk has increased significantly and Investments at amortised cost 41.96 6.29 35.67
are credit impaired
Loans at amortised cost 110.86 110.86 -
TOTAL 42,096.27 766.45 41,329.82

(` in Crores)
As at March 31, 2017

Particulars Carrying Amount

Gross Carrying
Asset Group Expected Credit Loss net of impairment
Amount (Exposure)
provision
Very High quality liquid assets Other Financial Assets and Loans to related 1,143.68 - 1,143.68
parties and others
Assets for which credit risk has not significantly increased Investments at amortised cost 17,172.72 327.40 16,845.32
from initial recognition
Loans at amortised cost 6,440.17 119.97 6,320.20
Assets for which credit risk has increased significantly but Investments at amortised cost 163.61 5.68 157.93
are not credit impaired
Loans at amortised cost 44.64 2.33 42.31
Assets for which credit risk has increased significantly and Investments at amortised cost 64.66 26.30 38.36
are credit impaired
Loans at amortised cost 115.85 50.78 65.07
TOTAL 25,145.33 532.46 24,612.87

a) Reconciliation of Loss Allowance

(` in Crores)
For the year ended March 31, 2018
Loss allowance measured at life-time
expected losses
Loss allowance
Investments and Loans measured at 12 month Financial assets
expected losses for which credit Financial assets
risk has increased which are credit-
significantly and not impaired
credit-impaired
Balance at the beginning of the year 447.37 8.01 77.08
Transferred to 12-month ECL 5.68 (5.68) -
Transferred to Lifetime ECL not credit impaired (6.86) 6.86 -
Transferred to Lifetime ECL credit impaired - collective provision - (2.33) 2.33
Charge to Statement of Profit and Loss (*)
On Account of Rate Change (45.01) 4.74 64.58
On Account of Disbursements 493.74 0.21 -
On Account of Repayments (259.21) (0.16) (24.90)
Balance at the end of the year 635.71 11.65 119.09
(*) The reason for increase in provision is due to increase in the loans & investments which is partially offset by a reduction in rate of ECL.

380 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

(` in Crores)
For the year ended March 31, 2017
Loss allowance measured at life-time
expected losses
Loss allowance
Investments and Loans measured at 12 month Financial assets for
expected losses which credit risk has Financial assets
increased significantly which are credit-
and not credit- impaired

Management Discussion & Analysis

impaired
Balance at the beginning of the year 279.35 4.02 60.54
Transferred to 12-month ECL - - -
Transferred to Lifetime ECL not credit impaired - - -
Transferred to Lifetime ECL credit impaired – collective provision - - -
Transferred to Lifetime ECL credit impaired – specific provision (2.90) - 2.90
Charge to Statement of Profit and Loss (#)
On Account of Rate Change (51.68) - (2.86)
On Account of Disbursements 306.07 5.68 39.59
On Account of Repayments (83.47) (1.69) (23.09)
Balance at the end of the year 447.37 8.01 77.08

Board & Management Profiles

(#) The reason for increase in provision is due to increase in the loans & investments which is partially offset by a reduction in rate of ECL.

b) Movement in Expected Credit Loss on undrawn loan commitments / letter of comfort:

(` in Crores)
As at As at
March 31, 2018 March 31, 2017
Balances as at the beginning of the year 6.36 39.93
Additions 11.07 5.96
Rate change - (0.33)
Amount used / reversed (6.36) (39.20)
Balances as at the end of the year 11.07 6.36
Classified as Current (Refer note 26) 11.07 6.36
Classified as Non-current (Refer note 20) - -

Statutory Reports
TOTAL 11.07 6.36

c) The amounts of Financial Assets outstanding in the Balance Sheet along with the undrawn loan commitments and letter of comforts issued (refer
note 49 (a)) as at the end of the reporting period represent the maximum exposure to credit risk.
Description of Collateral held as security and other credit enhancements

The Group generally ensures a security cover of 100-200% of the proposed facility amount. The Group periodically monitors the quality as well as
the value of the security to meet the prescribed limits. The collateral held by the Group varies on case to case basis and includes:

i) First / Subservient charge on the Land and / or Building of the project or other projects
ii) First / Subservient charge on the fixed and current assets of the borrower
iii) Hypothecation over receivables from funded project or other projects of the borrower
Financial Statements

iv) Pledge on Shares of the borrower or their related parties

v) Pledge on investment in shares made by borrower entity
vi) Guarantees of Promoters / Promoter Undertakings
vii) Post dated / Undated cheques

As at the reporting date, the ratio of value of the collateral held as security for the credit impaired financial assets to the exposure at default for
these assets is assessed at 0.23 : 1.

Annual Report 2017-18 | 381

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

d) The credit impaired assets as at the reporting dates were secured by charge on land and building and project receivables amounting to:
(` in Crores)
As at As at
March 31, 2018 March 31, 2017
Value of Security 35.67 105.36

Collateral taken over by the Group against recovery on credit impaired asset:
The Group has taken possession of a residential property which was mortgaged as collateral to recover dues on a credit impaired asset. The
carrying value of the collateral is ` 15.91 Crores and accounted for as asset held for sale.

51. MOVEMENT IN PROVISIONS:

(` in Crores)
Provisions for Grants -
Litigations / Disputes Onerous Contracts Incentive
Committed
Particulars
As at March 31, As at March 31, As at March 31, As at March 31,
2018 2017 2018 2017 2018 2017 2018 2017
Balances as at the beginning of the year 3.50 13.39 17.88 28.83 9.36 17.19 29.48 22.60
Additions - - - - - - - 7.62
Unwinding of Discount - - 1.38 2.72 - - - -
Amount used - - (12.92) (13.25) (6.95) (6.12) - -
Revaluation of closing balances - - - (0.42) (1.12) (0.65) 0.16 (0.74)
Unused amounts reversed - (9.89) - - - (1.06) - -
Balances as at the end of the year 3.50 3.50 6.34 17.88 1.29 9.36 29.64 29.48
Classified as Non-current (Refer note 20) - - - 4.91 1.29 4.25 - 29.48
Classified as Current (Refer note 26) 3.50 3.50 6.34 12.97 - 5.11 29.64 -
TOTAL 3.50 3.50 6.34 17.88 1.29 9.36 29.64 29.48

Provision for litigation / disputes represents claims against the Group not acknowledged as debts that are expected to materialise in respect of matters under litigation.
Future cash outflows are determinable only on receipt of judgments/decisions pending with various forums/authorities.
Provision for Onerous contracts represents the amounts provided for contracts where the unavoidable costs of meeting the obligations under the contract exceed the
economic benefits expected to be received under it.
Provision for grants represent expected contributions to be paid in FY 2018-19.
Provision for incentive represent stock-based compensation for certain employees in a subsidiary.

52. T he Chief Operating Decision maker of the Company examines the Group’s performance both from a product offerings and from a geographic
perspective. From a product perspective, the management has identified the following reportable segments:
1. Pharmaceuticals Manufacturing and Services
2. Financial Services
3. Healthcare Insights & Analytics

1. Pharmaceuticals Manufacturing and Services: In this segment, the Group has a strong presence in Pharma Solutions, Critical Care, Consumer
Products Services and Imaging. The Company and certain subsidairies act as a Contract Development and manufacturing organization offering
both APIs and formulations. The Group's critical care business deals in the inhalation anesthesia market. The group's consumer products
business is primarily an India-centric consumer healthcare business with strong brands portfolio. The Group also has a presence in Imaging
business; a subsidiary has US FDA and European Commission approval for the commercial sale of its diagnostic imaging agent.

2. Financial Services: Company's financial services segment offers a complete suite of financial products to meet the diverse needs of its customers.
The Company lends to various real estate developers and under special situation opportunities in various sectors and has investments in
Shriram Group, through which the Company has exposure to retail financing segments. The Group has recently launched a retail housing
finance vertical.

382 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

3. Healthcare Insights and Analytics: PEL’s Healthcare Insights & Analytics business, Decision Resources Group (DRG), is a market-leading decision-
support platform in the healthcare information services space. DRG provides indispensable insights to life sciences companies as well as
healthcare providers and payers through a variety of high value-added data and analytics, research reports, and knowledge-based services.
These offerings enable customers to make informed investment, cost containment and strategic business decisions in their chosen markets.

(` in Crores)
Pharmaceuticals manufacturing
Financial services Healthcare Insights & Analytics Total

Management Discussion & Analysis

Particulars and services
March 2018 March 2017 March 2018 March 2017 March 2018 March 2017 March 2018 March 2017
Revenue from operations 4,448.57 3,972.87 4,981.57 3,351.50 1,209.21 1,222.38 10,639.35 8,546.75
Segment Results 800.06 592.82 1,993.32 1,283.67 167.71 214.26 2,961.09 2,090.75
Add: Unallocated Income / (Net of unallocated cost) 52.12 37.71
Less: Finance cost (Unallocated) 572.11 436.50
Less: Depreciation 477.33 381.70
Profit before share of net profits of investments 1,963.77 1,310.26
accounted for using equity method and tax
Add: Share of net profit of associates and joint 280.09 169.90
ventures accounted for using the equity method
Profit Before Tax 2,243.86 1,480.16

Board & Management Profiles

Less: Tax (Credit) / Expenses (2,876.42) 228.12
Profit for the year 5,120.28 1,252.04

Included in the above Segment results, are the Exceptional Items as mentioned below:
(` in Crores)
Pharmaceuticals manufacturing
Total
Particulars and services
March 2018 March 2017 March 2018 March 2017
Severance Pay - (9.95) - (9.95)
TOTAL - (9.95) - (9.95)

Segment results of Pharmaceuticals and Healthcare Insights & Analytics segment represent Earnings before Interest, Tax, Depreciation and Amortisation and Segment
results of Financial services represent Earnings before Tax, Depreciation and Amortisation.

Statutory Reports
Other Information
(` in Crores)
Pharmaceuticals manufacturing
Financial services Healthcare Insights & Analytics Total
Particulars and services
March 2018 March 2017 March 2018 March 2017 March 2018 March 2017 March 2018 March 2017
Segment Assets 8,378.75 7,086.32 52,659.63 33,003.70 5,475.97 5,846.02 66,514.35 45,936.04
Unallocable Corporate Assets 6,169.04 2,303.32
Total Assets 72,683.39 48,239.36
Segment Liabilities 1,330.13 1,565.22 35,787.37 22,478.04 475.92 1,086.20 37,593.42 25,129.46
Unallocable Corporate Liabilities 8,644.58 8,227.33
Financial Statements

Total Liabilities 46,238.00 33,356.79

Capital Expenditure 551.56 3,104.05 25.36 31.26 111.46 114.59 688.38 3,249.90
Unallocable Capital Expenditure 173.05 408.80
Depreciation and amortisation 375.67 290.41 3.66 2.38 98.00 88.90 477.33 381.70
Non-Cash expenditure other than depreciation and 15.32 6.76 238.71 154.98 2.97 1.11 257.00 162.85
amortisation
The above segment assets and unallocated assets
include:
Investment in associates and joint ventures 3,010.63 2,752.54
accounted for by the equity method

Annual Report 2017-18 | 383

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

Geographical Segments
(` in Crores)
Within India Outside India Eliminations Total
Particulars
March 2018 March 2017 March 2018 March 2017 March 2018 March 2017 March 2018 March 2017
Revenue from operations 5,776.57 4,234.18 5,176.40 4,585.12 (313.62) (272.55) 10,639.35 8,546.75
Carrying amount of Non-current Assets* 2,439.93 2,138.08 9,334.45 9,113.11 35.79 0.27 11,810.17 11,251.46

* Other than Financial assets, deferred tax assets and post- employment benefit assets
No customer contributed more than 10% of the total revenue of the Group

53) INCOME TAXES RELATING TO OPERATIONS

a) Tax expense recognised in statement of profit and loss
(` in Crores)
Year Ended Year Ended
March 31, 2018 March 31, 2017
Current tax
In respect of the current year 823.95 440.52
In respect of prior years 26.73 44.94
850.68 485.46
Deferred tax
Deferred Tax, net (157.92) (257.34)
Deferred Tax on account of merger of subsidiaries (3,569.18) -
(3,727.10) (257.34)
Total tax expense recognised (2,876.42) 228.12

b) Tax expense recognised in other comprehensive income

(` in Crores)
Year Ended Year Ended
March 31, 2018 March 31, 2017
Deferred tax
Arising on income and expenses recognised in other comprehensive income:
Exchange loss on long-term loans transferred to OCI (86.68) (51.57)
Fair value remeasurement of hedging instruments entered into for cash flow hedges (2.51) 1.63
Changes in fair values of equity instruments (22.95) -
Remeasurement of defined benefit obligation 2.08 (1.41)
Total tax expense recognised (110.06) (51.35)

c) Deferred tax balances

The following is the analysis of deferred tax assets/(liabilities) presented in the consolidated statement of financial position:

(` in Crores)
As at As at
March 31, 2018 March 31, 2017
Deferred tax assets (net) 4,244.40 625.21
Deferred tax liabilities (net) (29.18) (30.75)
4,215.22 594.46

384 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

Deferred tax assets and liabilities are recognised for the future tax consequences of temporary differences between the carrying values of assets and
liabilities and their respective tax bases, and unutilised business loss and depreciation carry-forwards and tax credits. Deferred tax assets are recognized
to the extent that it is probable that future taxable income will be available against which the deductible temporary differences, unused tax losses,
depreciation carry-forwards and unused tax credits could be utilised.

Movement of deferred tax during the year ended March 31, 2018

Management Discussion & Analysis

(` in Crores)
Foreign Recognised
Recognised in
Opening Currency in other
Particulars statement of Closing balance
balance Translation comprehensive
profit and loss
Impact income
Deferred tax (liabilities)/assets in relation to:
Measurement of financial assets at amortised cost / fair value 82.46 26.97 - (22.95) 86.48
Provision for expected credit loss on financial assets (including commitments) 177.91 82.49 - - 260.40
Other Provisions 7.41 (0.07) - - 7.34
Amortisation of expenses which are allowed in current year 2.56 (1.11) - - 1.45
Disallowances for items allowed on payment basis 41.61 49.18 - 2.08 92.87
Effect of recognition of lease rent expense on straight-line basis 2.50 (0.38) - - 2.12
Unrealised profit margin on inventory 40.32 (3.35) - - 36.97

Board & Management Profiles

Goodwill on merger of wholly-owned subsidiaries (Refer Note 39 (a)) - 3,569.18 - - 3,569.18
Property, Plant and Equipment and Intangible assets (166.45) (87.98) - - (254.43)
Measurement of financial assets at amortised cost/fair value - (19.27) - - (19.27)
Measurement of financial liabilities at amortised cost (18.65) 12.40 - - (6.25)
Fair value measurement of derivative contracts (2.41) (7.86) - - (10.27)
Fair Valuation of Investment (15.43) 3.69 - - (11.74)
Unamortised Distribution Expenses (6.70) 2.68 - - (4.02)
Share of undistributed earnings of associates (11.60) (4.77) - - (16.37)
Other temporary differences 3.10 (1.41) - - 1.69
Cash flow hedges (1.63) - - (2.51) (4.14)
Deferred tax on exchange differences on long-term loans designated as net - 86.68 - (86.68) -

Statutory Reports
investments transferred to OCI
Brought forward losses 76.35 11.67 3.72 - 91.74
Unused tax credit (MAT credit entitlement) 383.11 8.36 - - 391.47
TOTAL 594.46 3,727.10 3.72 (110.06) 4,215.22

Financial Statements

Annual Report 2017-18 | 385

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

Movement of deferred tax during the year ended March 31, 2017
(` in Crores)
Recognised
Recognised in
Opening Utilised during in other
Particulars statement of Closing balance
balance the year comprehensive
profit and loss
income
Deferred tax (liabilities)/assets in relation to:
Measurement of financial assets at amortised cost / fair value 53.07 29.39 - - 82.46
Provision for expected credit loss on financial assets (including commitments) 129.96 47.95 - - 177.91
Other Provisions 4.77 2.64 - - 7.41
Amortisation of expenses which are allowed in current year 3.67 (1.11) - - 2.56
Disallowances for items allowed on payment basis 38.39 1.81 - 1.41 41.61
Effect of recognition of lease rent expense on straight-line basis 2.74 (0.24) - - 2.50
Unrealised profit margin on inventory - 40.32 - - 40.32
Property, Plant and Equipment and Intangible assets (139.46) (26.99) - - (166.45)
Measurement of financial liabilities at amortised cost (4.29) (14.36) - - (18.65)
Fair value measurement of derivative contracts (3.07) 0.66 - - (2.41)
Fair Valuation of Investment (8.21) (7.22) - - (15.43)
Unamortised Distribution Expenses (9.54) 2.84 - - (6.70)
Share of undistributed earnings of associates (10.75) (0.85) - - (11.60)
Other temporary differences (5.90) 10.90 - (1.90) 3.10
Cash flow hedges - - - (1.63) (1.63)
Deferred tax on exchange differences on long-term loans designated as net - (51.57) - 51.57 -
investments transferred to OCI
Brought forward losses - 76.35 - - 76.35
Unused tax credit (MAT credit entitlement) 236.29 146.82 - - 383.11
TOTAL 287.67 257.34 - 49.45 594.46

386 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

The income tax expense for the year can be reconciled to the accounting profit as follows:
(` in Crores)
For the year ended For the year ended
Particulars
March 31, 2018 March 31, 2017
Consolidated Profit before tax 1,963.77 1,310.26
Income tax expense calculated at 34.608% (2016-17: 34.608%) 679.62 453.45
Effect of expenses that are not deductible in determining taxable profit 46.30 77.50

Management Discussion & Analysis

Utilisation of previously unrecognised tax losses (93.50) (323.79)
Effect of incomes which are taxed at different rates 20.45 (11.09)
Effect of incomes which are exempt from tax (21.78) (24.73)
Effect of expenses for which weighted deduction under tax laws is allowed (6.82) (18.18)
Effect of previously unrecognised tax losses used to reduce defered tax expense (42.31) (76.35)
Tax provision for earlier years 26.73 44.94
Tax losses for which no deferred income tax is recognised 63.03 83.34
Temporary differences for which no deferred income tax was recognised 38.85 8.14
Deferred tax on goodwill on merger of wholly-owned subsidiaries (Refer Note 39 (a)) (3,569.18) -
Unrealised profit margin on inventory 9.81 (40.32)
Effect of deduction in tax for interest on Compulsory Convertible Debentures (51.91) -

Board & Management Profiles

Foreign Exchange gains subject to taxation on realised basis 11.58 -
Deferred tax on exchange differences on long-term loans designated as net investments transferred to OCI - 51.57
Share of undistributed earnings of associates 4.77 0.85
Effect on deferred tax balances due to the changes in income tax rate 0.49 -
Others 7.45 2.79
Income tax expense recognised in consolidated statement of profit and loss (2,876.42) 228.12

The tax rate used for the reconciliations above is the corporate tax rate of 34.608% for the year 2017-18 and 2016-17 payable by corporate entities in
India on taxable profits under tax law in Indian jurisdiction.

As at March 31, 2018, the Group has recognised Deferred Tax Asset of ` 3,569.18 Crores (Previous year NIL) in respect of tax deductible Goodwill arising
on merger of its subsidiaries (Refer Note 39(a)).

Statutory Reports
In assessing the realizability of deferred tax assets, the Group considers the extent to which it is probable that the deferred tax asset will be realized.
The ultimate realization of deferred tax assets is dependent upon the generation of future taxable profits during the periods in which those temporary
differences and tax loss carry-forwards become deductible. The Group considers the expected reversal of deferred tax liabilities, projected future taxable
income and tax planning strategies in making this assessment.

Based on the level of historical taxable income and projections for future taxable income over the periods in which the deferred income taxes are
deductible, the Group believes that it is probable that the Group will realize the benefits of this deferred tax asset. The amount of deferred tax asset
considered realisable, however, could be reduced in the near term if the estimates of future taxable income during the carry-forward period are reduced.

In addition to this, during the year, the Group has recognised Deferred Tax Asset of ` 42.31 Crores (Previous Year: ` 76.35 Crores) on unused tax losses,
Financial Statements

considering profits in the past 2 years and reasonable certainty of realisation of such deferred tax asset in the future years.

Deferred tax asset amounting to ` 468.69 Crores and `677.08 Crores (excluding the amount already recognised to the extent of Deferred Tax Liabilties
amounting ` 27.91 Crores and ` 57.49 Crores) as at March 31, 2018 and March 31, 2017, respectively in respect of unused tax losses was not recognized
by the Group, considering that the Company and its subsidiaries had a history of tax losses for recent years. Unrecognized Deferred tax of ` 178.70 Crores
and ` 198.41 Crores as at March 31, 2018 and March 31, 2017 are attributable to carry forward tax losses which are not subject to expiration dates. The
remaining unrecognized deferred tax of ` 289.99 Crores and ` 478.67 Crores as at March 31, 2018 and March 31, 2017 respectively are attributable to
carry forward tax losses which expires in various years through fiscal 2038.

Annual Report 2017-18 | 387

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

The Company has calculated its tax liability for current domestic taxes after considering MAT. The excess tax paid under MAT provisions over and above
normal tax liability can be carried forward and set-off against future tax liabilities computed under normal tax provisions. The Company was required
to pay MAT during the current and previous year and accordingly, a deferred tax asset of ` 391.47 Crores and ` 383.11 Crores has been recognized in
the statement of financial position as of March 31, 2018 and 2017 respectively, which can be carried forward for a period of 15 years from the year of
recognition.

54 (A). DISCLOSURES MANDATED BY SCHEDULE III BY WAY OF ADDITIONAL INFORMATION

Net Assets (total assets minus Share in Other Comprehensive Share in Total Comprehensive
Share in Profit or (loss) for the
total liabilities) Income for the year ended Income for the year ended
year ended March 31, 2018
as at March 31, 2018 March 31, 2018 March 31, 2018
As a % of As a % of
Name of the entity
As a % of As a % of Consolidated Consolidated
Amount Amount Amount Amount
Consolidated Consolidated Other Total
(` in Crores) (` in Crores) (` in Crores) (` in Crores)
net assets profit or (loss) Comprehensive Comprehensive
Income Income
Parent
Piramal Enterprises Limited 80.68% 21,336.85 10.13% 518.47 93.38% 640.42 19.96% 1,158.89
Subsidiaries
Indian
PHL Fininvest Private Limited 0.19% 49.56 0.05% 2.39 0.00% - 0.04% 2.39
Searchlight Health Private Limited (formerly 0.09% 24.32 -0.05% (2.49) 0.00% - -0.04% (2.49)
known as Health Superhiway Private Limited)
Piramal Capital Limited (Up to March 30, 2018) 0.00% - 0.00% 0.07 0.00% - 0.00% 0.07
(Refer note 39 (a))
Piramal Fund Management Private Limited 0.48% 127.04 0.15% 7.72 0.20% 1.35 0.16% 9.07
Piramal Finance Limited (formerly known as 0.00% - 19.88% 1,017.93 0.62% 4.28 17.61% 1,022.21
Piramal Finance Private Limited) (up to March 30,
2018) (Refer note 39 (a))
Piramal Housing Finance Limited (formerly 30.00% 7,934.33 -0.27% (13.79) 0.00% - -0.24% (13.79)
known as Piramal Housing Finance Private
Limited) (Refer note 39 (a))
PEL Finhold Private Limited 0.00% - 0.00% - 0.00% - 0.00% -
Piramal Investment Advisory Services Private 0.01% 3.08 0.00% (0.02) 0.00% - 0.00% (0.02)
Limited
Piramal Consumer Products Private Limited 0.00% 0.01 0.00% (0.00) 0.00% - 0.00% (0.00)
Piramal Systems & Technologies Private Limited -0.01% (2.53) -0.02% (1.19) 0.00% - -0.02% (1.19)
Piramal Investment Opportunities Fund 0.06% 15.01 0.01% 0.68 0.00% - 0.01% 0.68
Piramal Asset Reconstruction Private Limited (Up 0.00% - 0.00% 0.00 0.00% - 0.00% 0.00
to July 18, 2017) (Refer note 39 (c))
PEL Asset Resurgence Advisory Private Limited 0.00% - -0.14% (6.98) 0.00% - -0.12% (6.98)
(Up to February 06, 2018) (Refer note 39 (c))
Foreign
Piramal International 0.00% - 0.00% - 0.00% - 0.00% -
Piramal Holdings (Suisse) SA 0.73% 193.79 -0.19% (9.53) 1.71% 11.75 0.04% 2.22
Piramal Imaging SA -1.59% (419.66) -1.78% (91.02) -3.06% (21.01) -1.93% (112.03)
Piramal Imaging GmbH 0.04% 10.62 0.03% 1.65 0.20% 1.38 0.05% 3.03
Piramal Imaging Limited -1.48% (390.17) -2.33% (119.52) -0.39% (2.66) -2.10% (122.18)
Piramal Technologies SA 0.03% 7.21 -0.07% (3.73) -0.08% (0.55) -0.07% (4.28)
INDIAREIT Investment Management Co. 0.25% 66.57 0.22% 11.51 0.00% - 0.20% 11.51
Piramal Asset Management Private Limited 0.00% 0.27 -0.03% (1.42) 0.00% - -0.02% (1.42)
Piramal Dutch Holdings N.V. 7.83% 2,069.37 -1.07% (54.71) 1.48% 10.17 -0.77% (44.54)
Piramal Healthcare Inc. 3.81% 1,006.65 0.82% 41.85 0.78% 5.35 0.81% 47.20

388 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

Net Assets (total assets minus Share in Other Comprehensive Share in Total Comprehensive
Share in Profit or (loss) for the
total liabilities) Income for the year ended Income for the year ended
year ended March 31, 2018
as at March 31, 2018 March 31, 2018 March 31, 2018
As a % of As a % of
Name of the entity
As a % of As a % of Consolidated Consolidated
Amount Amount Amount Amount
Consolidated Consolidated Other Total
(` in Crores) (` in Crores) (` in Crores) (` in Crores)
net assets profit or (loss) Comprehensive Comprehensive
Income Income
Piramal Critical Care, Inc. 0.98% 258.91 3.33% 170.41 0.34% 2.32 2.97% 172.73

Management Discussion & Analysis

Piramal Pharma Inc. -0.04% (9.71) -0.12% (5.92) -0.01% (0.08) -0.10% (6.00)
PEL Pharma Inc. 0.11% 29.79 -0.38% (19.68) 0.00% 0.03 -0.34% (19.65)
Ash Stevens LLC 1.24% 329.24 0.77% 39.20 0.28% 1.90 0.71% 41.10
Piramal Pharma Solutions Inc. (formerly known -0.38% (100.57) -0.81% (41.43) -0.10% (0.69) -0.73% (42.12)
as Coldstream Laboratories Inc.)
Piramal Critical Care Italia, S.P.A 0.02% 5.21 -0.11% (5.75) 0.18% 1.22 -0.08% (4.53)
Piramal Critical Care Deutschland GmbH 0.03% 7.48 -0.14% (7.10) 0.15% 1.02 -0.10% (6.08)
Piramal Healthcare (UK) Limited 1.46% 385.25 1.88% 96.44 5.26% 36.09 2.28% 132.53
Piramal Healthcare Pension Trustees Limited 0.00% - 0.00% - 0.00% - 0.00% -
Piramal Critical Care Limited 0.92% 243.48 0.70% 35.87 0.53% 3.66 0.68% 39.53
Piramal Healthcare (Canada) Limited 0.62% 163.34 0.86% 44.17 0.75% 5.11 0.85% 49.28

Board & Management Profiles

Piramal Critical Care South Africa (Pty) Ltd 0.01% 2.18 -0.05% (2.44) 0.01% 0.03 -0.04% (2.41)
Piramal Critical Care B.V. 0.00% - 0.00% - 0.00% - 0.00% -
Piramal Critical Care Pty. Ltd. 0.00% - 0.00% - 0.00% - 0.00% -
Piramal Dutch IM Holdco B.V. 0.51% 135.37 0.00% (0.07) 0.10% 0.68 0.01% 0.61
PEL-DRG Dutch Holdco B.V. (and Subsidaries) -0.89% (234.92) -4.94% (252.91) 3.01% 20.63 -4.00% (232.28)
Non-Controlling Interests in all subsidiaries -0.05% (12.00) -0.02% (1.21) 0.00% - -0.02% (1.21)
Associates (Investment as per the equity
method)
Indian
Allergan India Private Limited 0.58% 152.83 0.92% 46.86 0.00% (0.03) 0.81% 46.83
Shriram Capital Limited (Refer note 4(a)) 0.00% 0.01 0.00% - 0.00% - 0.00% -
Piramal Phytocare Limited 0.00% - -0.02% (0.88) 0.00% - -0.02% (0.88)

Statutory Reports
Foreign
Bluebird Aero Systems Limited 0.15% 38.99 -0.03% (1.50) 0.00% - -0.03% (1.50)
Context Matters, Inc. (Up to August 15, 2017) 0.00% - 0.00% - 0.00% - 0.00% -
(Refer note 40 (A) (ii))
Joint Venture (Investment as per the equity
method)
Indian
Convergence Chemicals Private Limited 0.11% 28.60 -0.12% (6.16) 0.00% 0.02 -0.11% (6.14)
Shrilekha Business Consultancy Private Limited 10.53% 2,784.05 4.74% 242.50 0.00% - 4.18% 242.50
(Refer note 4(a))
India Resurgence ARC Private Limited (formerly 0.00% 1.03 0.00% 0.03 0.00% - 0.00% 0.03
known as Piramal Assets Reconstruction Private
Financial Statements

Limited) (Refer Note 39 (c))

India Resurgence Asset Management Business 0.02% 5.12 -0.01% (0.76) 0.00% - -0.01% (0.76)
Private Limited (formerly known as PEL Asset
Resurgence Advisory Private Limited) (Refer Note
39 (c))
Foreign
Asset Resurgence Mauritius Manager (Refer Note 0.00% - 0.00% - 0.00% - 0.00% -
39 (c))
Consolidation Adjustments -37.06% (9,800.61) 68.21% 3,492.74 -5.33% (36.57) 59.53% 3,456.17
TOTAL 100.00% 26,445.39 100.00% 5,120.28 100.00% 685.82 100.00% 5,806.10

Annual Report 2017-18 | 389

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

54 (B). DISCLOSURES MANDATED BY SCHEDULE III BY WAY OF ADDITIONAL INFORMATION

Net Assets (total assets minus Share in Other Comprehensive Share in Total Comprehensive
Share in Profit or (loss) for the
total liabilities) Income for the year ended Income for the year ended March
year ended March 31, 2017
as at March 31, 2017 March 31, 2017 31, 2017
As a % of As a % of
Name of the entity
As a % of As a % of Consolidated Consolidated
Amount Amount Amount Amount
Consolidated Consolidated Other Total
(` in Crores) (` in Crores) (` in Crores) (` in Crores)
net assets profit or (loss) Comprehensive Comprehensive
Income Income
Parent
Piramal Enterprises Limited 96.91% 14,422.60 62.04% 776.78 123.95% 845.21 83.87% 1,621.99
Subsidiaries
Indian
PHL Fininvest Private Limited 0.32% 47.18 1.63% 20.36 0.00% - 1.05% 20.36
Searchlight Health Private Limited 0.18% 26.84 -0.05% (0.65) 0.00% - -0.03% (0.65)
Piramal Capital Limited 0.01% 2.00 0.00% - 0.00% - 0.00% -
Piramal Fund Management Private Limited 0.80% 119.05 2.99% 37.38 -0.72% (4.88) 1.68% 32.50
Piramal Finance Limited (Earlier Piramal Finance 23.00% 3,423.67 20.87% 261.25 0.31% 2.08 13.62% 263.33
Private Limited)
PEL Finhold Private Limited 0.00% 0.01 0.00% - 0.00% - 0.00% -
Piramal Investment Advisory Services Private 0.02% 3.11 0.00% 0.02 0.00% - 0.00% 0.02
Limited
Piramal Consumer Products Private Limited 0.00% 0.01 0.00% (0.00) 0.00% - 0.00% (0.00)
Piramal Systems & Technologies Private Limited -0.01% (1.34) -0.41% (5.10) 0.00% - -0.26% (5.10)
Piramal Investment Opportunities Fund 0.10% 14.99 0.14% 1.80 0.00% - 0.09% 1.80
Piramal Asset Reconstruction Private Limited 0.01% 2.01 0.01% 0.07 0.00% - 0.00% 0.07
PEL Asset Resurgence Advisory Private Limited 0.02% 3.24 -0.14% (1.70) 0.00% - -0.09% (1.70)
Foreign
Piramal International 0.00% - 0.00% - 0.00% - 0.00% -
Piramal Holdings (Suisse) SA 1.29% 191.57 0.36% 4.46 -2.07% (14.11) -0.50% (9.65)
Piramal Imaging SA -2.12% (314.81) -4.55% (56.98) 2.86% 19.51 -1.94% (37.47)
Piramal Imaging GmbH 0.05% 7.58 0.15% 1.87 -0.09% (0.63) 0.06% 1.24
Piramal Imaging Limited -1.80% (268.03) -6.06% (75.86) 0.99% 6.73 -3.57% (69.13)
Piramal Technologies SA 0.04% 6.59 -0.18% (2.23) -0.09% (0.63) -0.15% (2.86)
INDIAREIT Investment Management Co. 0.37% 54.65 0.59% 7.36 0.00% - 0.38% 7.36
Piramal Asset Management Private Limited 0.00% 0.08 -0.03% (0.32) 0.00% - -0.02% (0.32)
Piramal Dutch Holdings N.V. 14.20% 2,113.93 -1.04% (13.05) 20.00% 136.40 6.38% 123.35
Piramal Healthcare Inc. 6.45% 959.45 3.22% 40.28 -3.01% (20.50) 1.02% 19.78
Piramal Critical Care, Inc. 0.58% 86.18 8.80% 110.20 -0.47% (3.20) 5.53% 107.00
Piramal Pharma Inc. -0.02% (3.71) 0.90% 11.33 -0.01% (0.06) 0.58% 11.27
PEL Pharma Inc. -0.10% (15.42) -1.30% (16.28) 0.08% 0.53 -0.81% (15.75)
Ash Stevens LLC 1.94% 288.15 -0.19% (2.42) -0.91% (6.22) -0.45% (8.64)
Piramal Pharma Solutions Inc. -0.39% (58.39) -0.56% (6.97) 0.18% 1.26 -0.30% (5.71)
Piramal Critical Care Italia, S.P.A 0.07% 9.75 -0.11% (1.44) -0.13% (0.86) -0.12% (2.30)
Piramal Critical Care Deutschland GmbH 0.04% 6.00 -0.41% (5.10) -0.10% (0.68) -0.30% (5.78)
Piramal Healthcare (UK) Limited 1.70% 252.79 2.92% 36.62 -5.10% (34.79) 0.09% 1.83
Piramal Healthcare Pension Trustees Limited 0.00% - 0.00% - 0.00% - 0.00% -
Piramal Critical Care Limited 1.37% 203.96 7.50% 93.86 -3.53% (24.10) 3.61% 69.76
Piramal Healthcare (Canada) Limited 0.77% 114.05 4.50% 56.38 -0.89% (6.04) 2.60% 50.34
Piramal Critical Care South Africa (Pty) Ltd 0.00% (0.11) -0.01% (0.11) 0.00% - -0.01% (0.11)
Piramal Dutch IM Holdco B.V. 0.91% 134.76 -0.02% (0.20) 0.91% 6.19 0.31% 5.99
PEL-DRG Dutch Holdco B.V. (and Subsidaries) -0.02% (2.88) -12.67% (158.69) 4.10% 27.98 -6.76% (130.71)

390 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

Net Assets (total assets minus Share in Other Comprehensive Share in Total Comprehensive
Share in Profit or (loss) for the
total liabilities) Income for the year ended Income for the year ended March
year ended March 31, 2017
as at March 31, 2017 March 31, 2017 31, 2017
As a % of As a % of
Name of the entity
As a % of As a % of Consolidated Consolidated
Amount Amount Amount Amount
Consolidated Consolidated Other Total
(` in Crores) (` in Crores) (` in Crores) (` in Crores)
net assets profit or (loss) Comprehensive Comprehensive
Income Income
Non-controlling Interests in all subsidiaries -0.09% (13.21) -0.02% (0.29) 0.00% - -0.01% (0.29)

Management Discussion & Analysis

Associates (Investment as per the equity
method)
Indian
Allergan India Private Limited 0.71% 106.00 2.25% 28.11 -0.01% (0.08) 1.45% 28.03
Piramal Phytocare Limited 0.01% 0.88 0.00% 0.01 0.00% - 0.00% 0.01
Shriram Capital Limited (Refer note 4 (a)) 0.00% 0.01 10.30% 129.00 0.00% - 6.67% 129.00
Foreign
Bluebird Aero Systems Limited 0.26% 38.38 -0.22% (2.80) 0.00% - -0.14% (2.80)
Context Matters 0.10% 15.11 -0.09% (1.10) 0.00% - -0.06% (1.10)
Joint Venture (Investment as per the equity
method)
Indian

Board & Management Profiles

Convergence Chemicals Private Limited 0.23% 34.74 -0.03% (0.32) 0.00% - -0.02% (0.32)
Shrilekha Business Consultancy Private Limited 17.18% 2,557.42 1.36% 17.00 0.00% - 0.88% 17.00
(Refer note 4 (a))
Consolidation Adjustments -65.08% (9,686.27) -2.44% (30.49) -36.25% (247.22) -14.36% (277.71)
TOTAL 100.00% 14,882.57 100.00% 1,252.04 100.00% 681.89 100.00% 1,933.93

55. FAIR VALUE MEASUREMENT

Financial Instruments by category:
a) Categories of Financial Instruments:
` in Crores
March 31, 2018 March 31, 2017

Statutory Reports
FVTPL FVTOCI Amortised Cost FVTPL FVTOCI Amortised Cost

Financial Assets
Investments 2,376.17 4,656.03 18,682.32 1,397.54 3,988.92 17,041.61
Loans 223.82 - 22,432.44 - - 7,335.73
Cash & Bank Balances - - 2,467.01 - - 1,540.90
Trade Receivables - - 1,355.45 - - 1,107.74
Other Financial Assets 5.32 - 209.74 14.69 - 220.83
2,605.31 4,656.03 45,146.96 1,412.23 3,988.92 27,246.81
Financial liabilities
Borrowings (including Current Maturities - - 44,160.80 - - 30,450.98
Financial Statements

of Long-Term Debt)
Trade Payables - - 874.29 - - 764.29
Other Financial Liabilities 141.94 - 318.36 172.52 - 1,214.76
141.94 - 45,353.45 172.52 - 32,430.03

Annual Report 2017-18 | 391

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

b) Fair Value Hierarchy and Method of Valuation

This section explains the judgements and estimates made in determining the fair values of the financial instruments that are (a) recognised and
measured at fair value and (b) measured at amortised cost and for which fair values are disclosed in the financial statements. To provide an
indication about the reliability of the inputs used in determining fair value, the group has classified its financial instruments into the three levels
prescribed under the accounting standard. An explanation of each level follows underneath the table.

` in Crores
March 31, 2018
Financial Assets Carrying
Notes Level 1 Level 2 Level 3 Total
Value
Measured at FVTPL – Recurring Fair Value Measurements
Investments
Investments in Preference Shares 1.70 1.70 1.70
Investments in debentures or bonds
Redeemable Non-Convertible Debentures i. 921.19 921.19 921.19
Investments in Mutual Funds ii. 1,270.16 1,270.16 1,270.16
Investment in Alternative Investment Fund/Venture Capital Funds vi. 183.12 183.12 183.12
Loans
Term Loans i. 223.82 223.82 223.82
Other Financial Assets
Derivative Financial Assets iii. 5.32 5.32 5.32
Measured at FVTOCI
Investments in Equity Instruments ii. 4,656.03 4,656.03 4,656.03
Measured at Amortised Cost for which fair values are disclosed
Investments
Investments in debentures or bonds (Gross of Expected Credit Loss) iv. 18,983.09 19,397.00 19,397.00
Loans
Term Loans (Gross of Expected Credit Loss) iv. 19,690.97 19,745.46 19,745.46
Intercorporate Deposits (Gross of Expected Credit Loss) iv. 3,207.16 3,198.72 3,198.72
Financial Liabilities
Measured at FVTPL - Recurring Fair Value Measurements
Contingent Consideration vii. 125.70 125.70 125.70
Derivative Financial Liabilities iii. 16.24 16.24 16.24
Measured at Amortised Cost for which fair values are disclosed
Borrowings (including Current Maturities of Long-Term Debt) (Gross) v. 44,160.80 44,168.00 44,168.00

392 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

` in Crores
March 31, 2017
Financial Assets
Notes Carrying Value Level 1 Level 2 Level 3 Total
Measured at FVTPL – Recurring Fair Value Measurements
Investments
Investments in Preference Shares 1.70 1.70 1.70
Investments in debentures or bonds

Management Discussion & Analysis

Redeemable Non-Convertible Debentures i. 987.86 987.86 987.86
Investments in Mutual Funds ii. 191.56 191.56 191.56
Investment in Alternative Investment Fund/Venture Capital Funds vi. 216.42 216.42 216.42
Other Financial Assets
Derivative Financial Assets iii. 14.69 14.69 14.69
Measured at FVTOCI
Investments in Equity Instruments ii. 3,988.92 3,988.92 3,988.92
Measured at Amortised Cost for which fair values are disclosed
Investments
Investments in debentures or bonds ( Gross of Expected Credit Loss) iv. 17,401.00 17,317.67 17,317.67
Loans

Board & Management Profiles

Term Loans ( Gross of Expected Credit Loss) iv. 6,548.59 7,039.98 7,039.98
Intercorporate Deposits ( Gross of Expected Credit Loss) iv. 43.78 41.39 41.39
Financial Liabilities
Measured at FVTPL - Recurring Fair Value Measurements
Contingent Consideration vii. 141.79 141.79 141.79
Derivative Financial Liabilities iii. 30.73 30.73 30.73
Measured at Amortised Cost for which fair values are disclosed
Borrowings (including Current Maturities of Long-Term Debt) (Gross) v. 30,450.98 30,720.32 30,720.32

Except for those financial instruments for which the carrying amounts are mentioned in the above table, the Company considers that the carrying
amounts recognised in the financial statements approximate their fair values.

Statutory Reports
For financial assets that are measured at fair value, the carrying amounts are equal to the fair values.

Level 1: Level 1 hierarchy includes financial instruments measured using quoted prices. This includes listed equity instruments, traded bonds and mutual
funds that have quoted price. The fair value of all equity instruments (including bonds) which are traded in the stock exchanges is valued using the closing
price as at the reporting period. The mutual funds are valued using the closing NAV.

Financial Statements

Annual Report 2017-18 | 393

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

Level 2: The fair value of financial instruments that are not traded in an active market (for example, traded bonds, over-thecounter derivatives) is
determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all
significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted
equity securities, contingent consideration, Debentures, Term Loans, investment in Alternate Investment Funds and ICDs included in level 3.

Valuation techniques used to determine the fair values:

i. Discounted cash flow method has been used to determine the fair value. The yield used for discounting has been determined based on trades,
market polls, levels for similar issuer with same maturity, spread over matrices, etc. For instruments where the returns are linked to the share price
of the investee Company the equity price has been derived using Monte Carlo simulation and local volatility model using the inputs like spot rate,
volatility surface, term structures and risk free rates from globally accepted 3rd party vendor for these data.

ii. This includes listed equity instruments and mutual funds which are fair valued using quoted prices and closing NAV in the market.

iii. This includes forward exchange contracts and cross currency interest rate swap. The fair value of the forward exchange contract is determined using
forward exchange rate at the balance sheet date. The fair value of cross currency interest rate swap is calculated as the present value of future cash
flow based on observable yield curves and forward exchange rates.

iv. Discounted cash flow method has been used to determine the fair value. The discounting factor used has been arrived at after adjusting the rate of
interest for the financial assets by the difference in the Government Securities rates from date of initial recognition to the reporting dates.

v. Fair values of borrowings are based on discounted cash flow using a current borrowing rate. They are classified as Level 3 values hierarchy due to
the use of unobservable inputs, including own credit risk. The discounting factor used has been arrived at after adjusting the rate of interest for the
financial liabilities by the difference in the Government Securities rates from date of initial recognition to the reporting dates.

vi. Discounted cash flow method has been used to determine the fair value. The discounting factor has been computed using a mix of past trends as
well as likely rate of return of the underlying projects.

vii. Discounted cash flow method has been used to determine the fair value of contingent consideration.

c) Fair value measurements using significant unobservable inputs (level 3)

The following table presents the changes in level 3 items for the period ended March 31, 2018 and March 31, 2017.

(` in Crores)
Alternative
Investment Equity Preference Contingent
Term loans Debentures Total
Fund/Venture Instruments Shares Consideration
Capital Fund
As at April 1, 2016 - 758.43 213.63 29.43 0.66 35.98 1,038.13
Acquisitions - 304.55 17.73 - 1.04 103.76 427.08
Losses recognised in profit or loss - - - - - 2.05 2.05
Gains / (Losses) recognised in profit or loss - 160.48 20.88 27.29 - - 208.65
Realisations - (235.60) (35.82) (56.72) - - (328.14)
As at March 31, 2017 - 987.86 216.42 - 1.70 141.79 1,347.77
Acquisitions 205.92 70.00 12.35 - - 2.93 291.20
Additional Accruals - - - - - 0.88 0.88
Gains / (Losses) recognised in profit or loss 17.90 161.03 (4.28) - - - 174.65
Exchange Fluctations - - - - - 0.85 0.85
Payments - - - - - (20.75) (20.75)
Realisations - (297.70) (41.37) - - - (339.07)
As at March 31, 2018 223.82 921.19 183.12 - 1.70 125.70 1,455.53

394 | Piramal Enterprises Limited

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

Strategic Overview
for the Year ended March 31, 2018

d) Valuation Process
The Company engages external valuation consultants to fair value below mentioned financial instruments measured at FVTPL. The main level 3
inputs used for investment in AIF / Venture capital fund, contingent consideration, term loans and debentures are as follows:

1) For Non-Convertible Debentures and Term Loans, Waterfall approach has been used to arrive at the yields for securities held by the Company.
For determining the equity prices Monte Carlo simulations and local volatility model using the inputs like spot rate, volatility surface, term
structures and risk free rates from globally accepted third party vendor for these data have been used.

Management Discussion & Analysis

2) For Alternative Investment Fund/Venture Capital Fund, Discounted cash flow method has been used to determine the fair value. The discounting
factor has been computed using a mix of past trends as well as likely rate of return of the underlying projects.

3) For Contingent consideration, fair value has been estimated by allocating probability to achievement of financial milestones. Discount rate is
determined using Capital Asset Pricing Model.

e) Sensitivity for instruments:

(` in Crores)
Fair value As Fair value As Sensitivity Impact for the Sensitivity Impact for the year
Significant Increase / Decrease in year ended March 31, 2018 ended March 31, 2017
Nature of the instrument on March on March
unobservable inputs* the unobservable input

Board & Management Profiles

31, 2018 31, 2017 FV Increase FV Decrease FV Increase FV Decrease
Non Convertible Debentures 921.19 987.86 Discount rate 1% 15.36 (15.53) 25.05 (24.23)
Equity component 10% (5% for Mar 17) 0.54 (0.41) - -
(projections)
Term Loans 223.82 - Discount rate 1% 3.63 (3.80) - -
Equity component 10% 8.48 (8.60) - -
(projections)
Alternative Investment Fund/ 183.12 216.42 Discount rate 1% 0.56 (0.57) 1.01 (1.03)
Venture Capital Fund
Cash Flow 5% 6.45 (4.66) 6.71 (6.71)
Contingent Consideration 125.70 141.79 Discount rate 1% 1.73 (1.73) 2.59 (2.59)
Expected Cash 10% 10.98 (10.82) 9.79 (9.79)
Outflow

Statutory Reports
* There were no significant inter-relationships between unobservable inputs that materially affect fair values.

f) Management uses its best judgment in estimating the fair value of its financial instruments. However, there are inherent limitations in any estimation
technique. Therefore, for substantially all financial instruments, the fair value estimates presented above are not necessarily indicative of all the
amounts that the Company could have realised or paid in sale transactions as of respective dates. As such, the fair value of the financial instruments
subsequent to the respective reporting dates may be different from the amounts reported at each year end.

56 (A) T he Group operates an incentive plan arrangement for certain employees of certain subsidiaries. The scheme provides a cash payment to the
employees based on a specific number of phantom shares at grant and share price of Piramal Enterprises Limited, the ultimate parent company
at the vesting date. The Cash payment is dependent on the performance of the underlying shares of Piramal Enterprises Limited and continued
employment on vesting date. The fair values of the award is calculated using the Black Scholes model at the grant date. The fair value is updated
Financial Statements

at each reporting date as the awards are accounted as cash settled plan. The inputs to the models are based on the Piramal Enterprises Limited
historic data, the risk free rate and the weighted average fair value of shares in the scheme at the reporting date. The amount expensed in the
current year relating to the plan is ` 7.12 Crores (Previous Year: ` 2.43 Crores). The Group considers these amount as not material and accordingly
has not provided further disclosures as required by IND AS 102 'Share Based Payments'.

56 (B) A
 subsidiary has issued certain options under the Scheme titled 'Health Superhiway Employees Stock Option Plan - 2011' (ESOP Plan) to its
employees. Each option comprises one underlying equity share of the subsidiary. The exercise price of each option shall be ` 54.10. The options
granted vests over a period of four years from the date of grant in proportions specified in the Scheme. Options may be exercised within three
years of vesting. Since the exercise price of the shares is much higher than the book value of the share of the subsidiary, there is no impact on
the earnings.

Annual Report 2017-18 | 395

CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (Contd.)

for the Year ended March 31, 2018

57 T he financial statements for the year ended March 31, 2018 include the results and financial position of an associate to whom Ind AS does not apply
currently and hence, the results are accounted based on currently applicable Indian GAAP.

58 S ubsequent to March 31, 2018, Board of Directors have approved a 'Scheme of Amalgamation' ( 'Scheme') of Piramal Phytocare Limited, an associate
of the Company with the Company and its respective shareholders. The Scheme is subject to approval of shareholders and other regulatory authorities
as applicable.

59 (A) O
 n October 25, 2017, 464,330 Compulsorily Convertible Debentures ('CCD') having face value of ` 107,600 per CCD were allotted to the CCD
holders for an aggregate amount of ` 4,996.19 Crores. Each CCD is convertible into 40 equity shares of ` 2 each. During the year, 225,000 Equity
shares were allotted by the Company upon exercise of options by the CCD holders.

Subsequent to March 31, 2018, 318,840 equity shares were allotted by the Company upon exercise of options by the CCD holders.

59 (B) D
 uring the year, the Company issued 8,310,275 Equity shares under Rights Issue at a price of ` 2,380 per share (including premium of ` 2,378 per
share). Out of the aforesaid issue, 7,485,574 equity shares were allotted by the Company on March 8, 2018 and 797,748 Rights Equity shares have
been Reserved for the CCD Holders (as per regulation 53 of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements)
Regulations, 2009) and 26,953 Rights Equity Shares have been kept in abeyance.

Proceeds from the right issue have been utilised upto March 31, 2018 in the following manner:

(` in Crores)
Particulars Planned Actual
a) Investment in Piramal Finance Limited (wholly-owned subsidiary) 750.00 750.00
b) Repayment or pre-payment, in full or part, of certain borrowings availed by the Company 1,000.00 878.91
c) General Corporate Purposes 216.22 -
Add: Issue related expenses * 11.63 6.05
TOTAL 1,977.85 1,634.96
Less: Right Shares held in Abeyance (6.41) -
Less: Right Shares reserved in favour of Compulsorily Convertible Debenture Holders (189.87) -
Less: Interest Income received from Fixed Deposits placed with Banks from Right Issue Proceeds - (1.39)
TOTAL 1,781.57 1,633.57
Unutilised proceeds kept as Fixed Deposit with Bank - 148.00

* The above utilisation does not include expenses of ` 1.49 Crores incurred other than through monitoring accounts opened for the purpose of Right Issue.

60. The financial statements have been approved for issue by Company's Board of Directors on May 28, 2018.

Signature to note 1 to 60 of the Consolidated financial statements.

For and on behalf of the Board of Directors

Ajay G. Piramal
Chairman

Vivek Valsaraj Leonard D'Souza

Chief Financial Officer Company Secretary

Mumbai, May 28, 2018

396 | Piramal Enterprises Limited

NOTICE
NOTICE is hereby given that the 71st Annual General Meeting of the
Members of Piramal Enterprises Limited will be held on Monday, July 30,
2018 at 3.00 p.m. at Rangaswar Auditorium, 4th Floor, Yashwantrao Chavan
Pratishthan, General Jagannathrao Bhosale Marg, Next to Sachivalaya
Gymkhana, Mumbai - 400 021, to transact the following business:
ORDINARY BUSINESS
1. To receive, consider and adopt the Audited Financial Statements
(Standalone & Consolidated) for the financial year ended on March 31,
2018 and the Reports of the Directors and Auditors thereon.
2. To declare dividend.
3. To appoint a Director in place of Ms. Nandini Piramal (DIN:
00286092), who retires by rotation in terms of Section 152(6) of the
Companies Act, 2013 and being eligible, offers herself for
re-appointment.
SPECIAL BUSINESS
4. Re-appointment of Mr. S. Ramadorai as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and all other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015 (including any amendment thereof), Mr. S. Ramadorai (DIN:
00000002), an Independent Director of the Company, whose term
of office as an Independent Director expires on March 31, 2019
and who is eligible for re-appointment and in respect of whom the
Company has received a notice in writing under Section 160 of the
Act, from a member proposing his candidature for the office of
Director, be and is hereby re-appointed as Independent Director of
the Company, not liable to retire by rotation to hold office for five
consecutive years for a term commencing from April 1, 2019 up to
March 31, 2024.”
5. Re-appointment of Mr. Narayanan Vaghul as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and all other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015 (including any amendment thereof), Mr. Narayanan Vaghul
(DIN: 00002014), an Independent Director of the Company, whose
term of office as an Independent Director expires on March 31,
2019 and who is eligible for re-appointment and in respect of whom
the Company has received a notice in writing under Section 160 of
the Act, from a member proposing his candidature for the office of
Director, be and is hereby re-appointed as Independent Director of
the Company, not liable to retire by rotation and to hold office for
five consecutive years for a term commencing from April 1, 2019 up
to March 31, 2024.”
6. Re-appointment of Dr. R.A. Mashelkar as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015 (including any amendment thereof), Dr. R.A. Mashelkar
(DIN: 00074119), an Independent Director of the Company, whose
term of office as an Independent Director expires on March 31,
2019 and who is eligible for re-appointment and in respect of whom
the Company has received a notice in writing under Section 160 of
the Act, from a member proposing his candidature for the office of
Director, be and is hereby re-appointed as Independent Director of
the Company, not liable to retire by rotation to hold office for five
consecutive years for a term commencing from April 1, 2019 up to
March 31, 2024.”
7. Re-appointment of Prof. Goverdhan Mehta as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and all other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015 (including any amendment thereof), Prof. Goverdhan Mehta
(DIN: 00350615), an Independent Director of the Company, whose
term of office as an Independent Director expires on March 31,
2019 and who is eligible for re-appointment and in respect of whom
the Company has received a notice in writing under Section 160 of
the Act, from a member proposing his candidature for the office of
Annual Report 2017-18 | 397
 Director, be and is hereby re-appointed as Independent Director of
the Company, not liable to retire by rotation to hold office for five
consecutive years for a term commencing from April 1, 2019 up to
March 31, 2024.”
8. Re-appointment of Mr. Keki Dadiseth as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and all other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015, including any amendment thereof, Mr. Keki Dadiseth (DIN:
00052165), an Independent Director of the Company, whose term of
office as an Independent Director expires on March 31, 2019 and who
is eligible for re-appointment and in respect of whom the Company
has received a notice in writing under Section 160 of the Act, from a
member proposing his candidature for the office of Director, be and
is hereby re-appointed as Independent Director of the Company, not
liable to retire by rotation to hold office for five consecutive years for
a term commencing from April 1, 2019 up to March 31, 2024.”
9. Re-appointment of Mr. Deepak Satwalekar as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and all other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015, including any amendment thereof, Mr. Deepak Satwalekar
(DIN: 00009627), an Independent Director of the Company, whose
term of office as an Independent Director expires on March 31,
2019 and who is eligible for re-appointment and in respect of whom
the Company has received a notice in writing under Section 160 of
the Act, from a member proposing his candidature for the office of
Director, be and is hereby re-appointed as Independent Director of
the Company, not liable to retire by rotation to hold office for five
consecutive years for a term commencing from April 1, 2019 up to
March 31, 2024.”
10. Re-appointment of Mr. Gautam Banerjee as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and all other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
398 | Piramal Enterprises Limited
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015 (including any amendment thereof), Mr. Gautam Banerjee
(DIN: 03031655), an Independent Director of the Company, whose
term of office as an Independent Director expires on March 31,
2019 and who is eligible for re-appointment and in respect of whom
the Company has received a notice in writing under Section 160 of
the Act, from a member proposing his candidature for the office of
Director, be and is hereby re-appointed as Independent Director of
the Company, not liable to retire by rotation to hold office for five
consecutive years for a term commencing from April 1, 2019 up to
March 31, 2024.”
11. Re-appointment of Mr. Siddharth Mehta as Independent Director
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT pursuant to the provisions of Sections 149, 152
read with Schedule IV and all other applicable provisions, if any, of
the Companies Act, 2013 (‘the Act’), the Companies (Appointment
and Qualification of Directors) Rules, 2014 (including any statutory
modification or re-enactment thereof for the time being in force)
and applicable provisions of the Securities and Exchange Board of
India (Listing Obligations and Disclosure Requirements) Regulations,
2015, including any amendment thereof, Mr. Siddharth Mehta (DIN:
06530606), an Independent Director of the Company, whose term
of office as an Independent Director expires on March 31, 2019
and who is eligible for re-appointment and in respect of whom the
Company has received a notice in writing under Section 160 of the
Act, from a member proposing his candidature for the office of
Director, be and is hereby re-appointed as Independent Director of
the Company, not liable to retire by rotation to hold office for five
consecutive years for a term commencing from April 1, 2019 up to
March 31, 2024.”
12. Re-appointment of Dr. (Mrs.) Swati A. Piramal as Vice-Chairperson
To consider and, if thought fit, to pass, the following resolution as a
Special Resolution:
“RESOLVED THAT subject to and in accordance with the provisions
of Sections 196, 197 and Schedule V read with the Companies
(Appointment and Remuneration of Managerial Personnel) Rules,
2014 and all other applicable provisions, if any, of the Companies
Act, 2013 (‘the Act’) (including any statutory modifications or
re-enactment thereof for the time being in force), approval of the
members be and is hereby accorded to the re-appointment of
Dr. (Mrs.) Swati A. Piramal (DIN: 00067125) as Whole – Time
Director designated as ‘Vice – Chairperson’ of the Company, liable
to retire by rotation with effect from November 20, 2017, for a
further period of 5 years, upon the terms and conditions including
payment of remuneration, perquisites and benefits as set out in the
draft of the Agreement to be entered into between the Company
and Dr. (Mrs.) Swati A. Piramal and main terms of which are set
out hereunder, which have been approved and recommended
by the Nomination and Remuneration Committee and the Board